Claims for Patent: 5,747,504

Summary for Patent: 5,747,504

Title:	Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
Abstract:	The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R1, R2 and R3 are identical or different and each denote hydrogen or an organic radical and R4 and R5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
Inventor(s):	Rainer Henning, Hansjorg Urbach, Volker Teetz, Rolf Geiger, Bernward Scholkens
Assignee:	Sanofi Aventis Deutschland GmbH
Application Number:	US08/709,286
Patent Claims:	1. A method for treating cardiac insufficiency in a mammal comprising the step of administering to a mammal in recognized need of, and for the purpose of said treatment, an amount of an angiotensin-converting enzyme inhibitor effective for said treatment, said angiotensin-converting enzyme inhibitor having the formula I: ##STR6## in which R is hydrogen, methyl, ethyl or benzyl; or a pharmaceutically acceptable salt thereof. 2. A method of treating cardiac insufficiency in a mammal comprising the step of administering to a mammal in recognized need of, and for the purpose of said treatment, an amount of angiotensin-converting enzyme inhibitor effective for said treatment, said angiotensin-converting enzyme inhibitor being N-(1-S-carboxy-3-phenyl-propyl)-S-alanyl-S-1,2,3,4-tetrahydroisoquinoline- 3-carboxylic acid or a pharmaceutically acceptable salt thereof. 3. The method according to claim 1, wherein said inhibitor or salt thereof is administered orally or parenterally.